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Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) 
inhibitors have shown clinical activity in epithelial ovarian cancer, 
leading both the US Food and Drug Administration (FDA) and 
the European Medicines Agency to approve olaparib for tumors 
characterized by BRCA1 and BRCA2 mutations. However, it is 
becoming increasingly evident that tumors that share molecular 
features with BRCA-mutant tumors—a concept known as 
BRCAness—also may exhibit defective homologous recombination 
DNA repair, and therefore will respond to PARP inhibition. A 
number of strategies have been proposed to identify BRCAness, 
including identifying defects in other genes that modulate 
homologous recombination and characterizing the mutational and 
transcriptional signatures of BRCAness. In addition to olaparib, a 
number of other PARP inhibitors are in clinical development. This 
article reviews the development of PARP inhibitors other than 
olaparib, and discusses the evidence for PARP inhibitors beyond 
BRCA1/2-mutant ovarian cancer.
Introduction
Epithelial ovarian cancer (EOC), which is the most lethal gyne­
cologic malignancy, is the fifth­leading cause of cancer­related 
deaths in women.1 The majority of women present with advanced­
stage disease, and eventually relapse after initial therapy.2 The cur­
rent standard of care is a combination of aggressive cytoreductive 
surgery and platinum­based chemotherapy, with a response to first­
line chemotherapy seen in 65% to 80% of patients.3 Despite high 
initial response rates, most patients die of their disease. The 5­year 
survival rate for those with advanced­stage disease is approximately 
5% to 22%.1 The current management of relapsed EOC is based 
on sensitivity to platinum chemotherapy. Although initial response 
rates are high, sensitivity to platinum therapy diminishes with 
time; the majority of patients eventually develop platinum­resistant 
disease.4­7 Although recent advances have led to improvements in 
progression­free survival (PFS), few have resulted in improved 
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overall survival, and recurrent ovarian cancer remains a 
lethal disease. As a consequence, considerable room for 
improvement remains. 
Our greater understanding of the cancer genome 
and the complex processes that underlie cancer develop­
ment and progression offers a fundamental change in the 
treatment of cancer. It is now possible to target molecular 
alterations and pathways directly. An example of this is 
the ability to target tumors with defective DNA repair by 
exploiting the molecular differences between tumor and 
normal cells, thereby inducing cancer­specific synthetic 
lethality. The best example of this to date is the use of 
poly(adenosine diphosphate­ribose) polymerase (PARP) 
inhibitors for the treatment of BRCA1- or BRCA2-mutant 
EOC.8,9 BRCA1 and BRCA2 are involved in the error­free 
repair of DNA double­strand breaks via the highly con­
served homologous recombination repair pathway, and 
are essential for the maintenance of genomic stability.10 
Cells with defective homologous recombination, such as 
those with BRCA1/2 mutations, rely on alternative means 
of DNA repair, including base excision repair, nucleotide 
excision repair, and mismatch repair, processes that are 
modulated by PARP. This defective homologous recom­
bination pathway renders the cells sensitive to PARP 
inhibition, a concept known as synthetic lethality.11,12 
The synthetic lethality between BRCA1/2 mutations and 
PARP inhibition is well established11,12 and is discussed in 
part 1 of this review.13 
It is becoming increasingly evident that tumors that 
share molecular features with BRCA­mutant tumors, a 
concept known as BRCAness, also may respond to simi­
lar therapeutic approaches. The BRCAness phenotype 
describes the situation whereby a homologous recombina­
tion defect exists in a tumor in the absence of a germline 
BRCA1 or BRCA2 mutation.14 As many as 30% to 50% 
of high­grade serous ovarian cancers are associated with 
defects in homologous recombination pathways,15,16 and 
targeting homologous recombination deficiency using 
PARP inhibitors has become one of the first genotype­
directed therapies for ovarian cancer.
Olaparib (Lynparza, AstraZeneca) is the most 
established PARP inhibitor to date. However, multiple 
other PARP inhibitors—including rucaparib (CO­
338), veliparib (ABT­888), niraparib (MK­4827), and 
talazoparib (BMN­673)—are in clinical development 
either as single agents or as a component of combination 
therapy for the management of EOC (Table 1). Early­
phase clinical studies with olaparib have confirmed the 
synthetic lethality previously observed in vitro, with 
dramatic responses to olaparib observed in patients with 
BRCA1/2­mutant EOC.17,18 As a result of these and other 
studies, olaparib has been licensed for patients with 
BRCA1/2­mutant ovarian cancer in both North America 
and Europe.19,20 In part 1 of this review, we discussed the 
evidence for the use of olaparib in ovarian cancer and 
the mechanisms behind BRCA1/2 and PARP inhibitor 
synthetic lethality.13 In this part, we consider the data 
regarding novel PARP inhibitors (other than olaparib) 
and evaluate the role for expanding the use of PARP 
inhibitors in ovarian cancer beyond BRCA1/2 mutations. 
Expanding the Scope of PARP Inhibition
Targeting Homologous Recombination Deficiency 
Dramatic responses to PARP inhibition have been 
observed in germline­associated BRCA1/2­mutated 
tumors. However, based on early clinical trials with PARP 
inhibitors, it was clear that a sensitive BRCA–wild­type 
cohort also existed, and that identifying these patients 
would be essential to increasing the utility of PARP 
inhibition in EOC. A number of sporadic EOCs are also 
defective in homologous recombination and share the 
BRCAness phenotype.15,16,21 Significant challenges exist in 
identifying these patients, and a number of approaches 
have been suggested for identifying those tumors 
characterized by BRCAness. This includes identifying 
defects in other genes that modulate homologous 
recombination and characterizing the mutational and 
transcriptional signatures of BRCAness. 
Not only did The Cancer Genome Atlas project 
identify almost­universal TP53 mutations (96%) in 
high­grade serous ovarian cancer, it also identified muta­
tions in homologous recombination pathway genes in 
approximately 50% of these cancers.15 In addition to 
germline mutations in BRCA1 (9%) and BRCA2 (8%), 
this included somatic mutations in BRCA1/2 (3%), ATM 
and ATR (2%), and the FANC family (5%), as well as 
hypermethylation of RAD51C (3%) and EMSY amplifi­
cation (8%), which is proposed to inactivate BRCA2.15,22 
In vitro studies have demonstrated that deficiencies in 
many of these genes and other homologous recombina­
tion proteins, such as checkpoint kinase 1 (CHEK1), 
check point kinase 2 (CHEK2), and cyclin­dependent 
kinase 12 (CDK12), also confer sensitivity to PARP inhi­
bition, although this remains to be prospectively validated 
in clinical populations.16,23­25 
In an attempt to further characterize homologous 
recombination deficiency in EOC, Pennington and 
colleagues employed targeted capture and massively 
parallel genomic sequencing to look for germline and 
somatic loss­of­function mutations in 30 genes, including 
13 homologous recombination genes in 390 EOCs.16 
Overall, 31% of EOCs had a deleterious germline (24%) 
and/or somatic (9%) mutation in 1 or more of the 13 
homologous recombination genes, with similar incidence 
noted in serous (31%) and nonserous histologies (28%, 
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P=.06). Both platinum sensitivity (P=.0002) and 
improved overall survival (P=.0006) were associated 
with the presence of a germline or somatic homologous 
recombination gene mutation.16 Although the majority 
of homologous recombination mutations were either 
germline or somatic BRCA1/2 mutations, 26% occurred 
within other homologous recombination genes. The 
authors hypothesized that these individuals would also 
have increased response rates to PARP inhibitors, and 
should be considered for inclusion in PARP inhibitor 
trials.16 Anecdotal reports support this. For example, 
a number of clinical responses to rucaparib have been 
observed in patients with both germline and somatic 
RAD51C mutations within the ongoing phase 2 ARIEL2 
study (Assessment of Rucaparib in Ovarian Cancer: 
Phase 2 Trial; NCT01891344).26 It is of interest that in 
this study by Pennington, similar rates of homologous 
recombination deficiency were noted in nonserous 
histology, including clear cell carcinoma, endometrioid 
carcinoma, and carcinosarcoma. These types of cancer 
normally are considered homologous recombination–
proficient, and therefore are not included in many clinical 
trials of PARP inhibitors.16 There was a greater proportion 
of non­BRCA homologous recombination deficiencies 
in the nonserous histology cohort, although BRCA1/2 
mutations did exist. These findings suggest that patients 
with nonserous histology also may be considered for 
studies of PARP inhibitors. 
Although using a targeted panel of homologous 
recombination genes is one approach to identifying 
tumors characterized by BRCAness, it remains to be 
tested prospectively. Furthermore, a number of limita­
tions exist with this approach. First, each individual 
homologous recombination gene defect—with the 
exception of BRCA1/2—is present at low frequency, and 
therefore a large number of genes need to be analyzed 
to capture all homologous recombination–deficient 
tumors. Secondly, not all homologous recombination 
genes contribute equally to the BRCA phenotype, and 
functional studies still are required to correlate many of 
the homologous recombination mutations to clinical 
responses. Finally, defective homologous recombination 
arises via a variety of mechanisms, which include epi­
genetic changes, gene amplifications, and chromosomal 
translocations, not all of which are identified using 
simple sequencing technologies. Rather than concen­
trating on identifying individual defects in homologous 
recombination genes, a number of groups have focused 
on the identification of a biomarker to identify tumors 
characterized by BRCAness—one that captures the 
diverse epigenetic and genetic mechanisms of homolo­
gous recombination. This approach utilizes the tran­
scriptional and mutational signatures of BRCAness. 
Identifying a BRCAness Biomarker
Transcriptional biomarkers usually consist of a pattern of 
gene expression that is associated with germline BRCA1/2 
gene defects and also is present in sporadic tumors. For 
example, Konstantinopoulos and colleagues interrogated 
publicly available gene expression data from BRCA1/2-
mutant or wild­type high­grade serous ovarian cancer to 
derive a BRCAness gene expression profile.27 This profile 
was validated in vitro and correlated with increased 
responsiveness to platinum and to PARP inhibitors in cell 
line models.27 The assay was then applied to a validation 
cohort of 70 patients with sporadic EOC. The authors 
noted that patients with a high BRCAness profile had 
improved disease­free survival and overall survival 
compared with those who had a BRCA wild­type profile, 
after correcting for traditional disease­specific prognostic 
markers.27 Although further prospective validation is 
required, in the future it may be possible to use gene 
expression profiling to identify patients with sporadic 
disease who might benefit from PARP inhibition. 
An alternative approach to the use of gene expres­
sion signatures is to classify tumors according to their 
under lying mutational spectrum.28 Owing to the reliance 
on error­prone DNA repair pathways, tumors with def­
ec tive homologous recombination have a characteristic 
mutational signature or “mutational scar.”29 Homolo­
gous recombination–deficient tumors harbor large (<15 
mega base) subchromosomal deletions, allelic imbalance, 
and single­nucleotide polymorphisms. Genotyping and 
comparative genomic hybridization have shown that the 
genomes of high­grade serous ovarian cancer harbor com­
mon loss of single parental alleles, which are detected as 
loss of heterozygosity (LOH).29,30 High levels of LOH are 
associated with reduced platinum resistance and improved 
PFS in patients with high­grade serous ovarian cancer.31 
Prospective validation of an LOH assay is ongoing 
within the ARIEL2 phase 2 study of rucaparib. Here, 
next­generation sequencing is performed on fresh tumor 
biopsies, allowing patients to be classified in 1 of 3 
molecularly defined subgroups: those with BRCA1/2­
mutant tumors (germline and somatic), those with 
BRCA-like tumors, and those whose tumors are bio­
marker­negative. BRCA-like tumors are defined as those 
with high levels of genomic LOH in the context of wild­
type BRCA.32 Early results suggest increased activity for 
rucaparib within the BRCA-like population compared 
with the low­LOH population, although the benefit was 
not quite as great as that seen in the BRCA1/2­mutant 
cohort (see below).32 We await with interest the final 
results, to see whether this homologous recombination 
deficiency LOH assay can predict an additional subset of 
patients with sporadic EOC who are likely to respond to 
PARP inhibition. 
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Other Genes Conferring PARP Inhibitor Sensitivity
Until recently, the role of PARP inhibitors has focused on 
homologous recombination deficient, high­grade serous 
ovarian cancer. However, in vitro data suggest that other 
molecular aberrations may sensitize tumors to PARP 
inhibition in other histologic subtypes. For example, 
deficiency in AT­rich interaction domain 1A (ARID1A), 
a key component of the chromatin­remodeling complex, 
sensitizes cancer cells to PARP inhibition in vitro and in 
vivo.33 ARID1A is recruited to DNA double­strand breaks, 
facilitates efficient processing of double­strand breaks, and 
sustains DNA damage signaling. Mutations in ARID1A 
are common in both clear cell and endometrioid ovarian 
epithelial carcinomas, occurring in up to 57% and 30% 
of cases, respectively.34,35 This finding suggests that a trial 
of PARP inhibitors should be used in these patients. Loss 
of phosphatase and tensin homolog (PTEN) function 
has been shown to sensitize tumors to PARP inhibition 
in endometrioid endometrial cancer owing to defects 
in repair of DNA double­strand breaks by homologous 
recombination. Therefore, loss of PTEN function may 
sensitize cells to PARP inhibition.36 PTEN mutations are 
common in endometrioid and clear cell ovarian cancer,37,38 
and these patients may therefore represent an additional 
group that may benefit from PARP inhibition. This use of 
PARP inhibitors requires clinical validation. 
It is clear that a subset of patients with BRCA1/2–
wild­type EOC exists who would benefit from PARP 
inhibition, but as yet it has not been established how to best 
identify this population. With improved understanding 
of PARP biology and homologous recombination–
directed biomarker studies, it will be possible to identify 
the population that is most likely to benefit. 
Novel PARP Inhibitors
In addition to olaparib, a number of novel PARP inhibitors 
are in various stages of clinical development (Table 1). 
Rucaparib 
Rucaparib is an oral PARP­1/2 inhibitor that also has 
activity against tankyrase 1 and 2 (TNKS1/2).39 The 
initial phase 1 trial established a recommended dose of 
600 mg twice daily and demonstrated early clinical activ­
ity in patients with both platinum­sensitive and platinum­
resistant ovarian and peritoneal cancers.39 Further evalu­
ation of rucaparib in recurrent ovarian cancer is ongoing. 
Results of the first part of ARIEL2, a phase 2 biomarker 
study in 206 women with relapsed platinum­sensitive 
high­grade serous or endometrioid cancer, recently were 
reported.26 As discussed earlier, ARIEL2 was designed to 
assess sensitivity to rucaparib in 3 prospectively defined 
molecular subgroups of patients who had received at least 
1 prior chemotherapy regimen. Overall response rates by 
Response Evaluation Criteria in Solid Tumors (RECIST) 
and CA 125 response criteria were 82%, 43%, and 22% 
for the BRCA1/2­mutant, BRCA-like, and biomarker­
negative populations, respectively, with median PFS 
of 286 days, 216 days, and 111 days. Interestingly, the 
median duration of response to rucaparib among the 
responders was similar in the BRCA1/2-mutant and 
BRCA-like cohorts (9.5 and 8.2 months, respectively), 
and work is ongoing to identify those patients with the 
BRCA-like phenotype who are most likely to respond. 
The same prospective molecular stratification of 
patients is being applied to 2 ongoing ovarian cancer trials: 
the second part of ARIEL2, a single­arm study in patients 
with high­grade ovarian cancer who have received at least 
3 prior chemotherapy regimens, and ARIEL3, a random­
ized maintenance study of rucaparib vs placebo in patients 
with high­grade ovarian cancer who have received at least 2 
platinum regimens (NCT01968213, Table 2). In addition 
to being explored for use as a single agent, rucaparib also 
has been combined with temozolomide in patients with 
melanoma, with some evidence of chemopotentiation.40 
Niraparib 
Niraparib is an orally bioavailable PARP­1/2 inhibitor 
that inhibits tumor growth in models with loss of BRCA 
and PTEN function.41 A total of 60 patients in the initial 
dose­finding study received 30 to 400 mg of oral nirapa­
rib daily in a 21­day cycle. A further 40 patients were 
enrolled in the study’s expansion phase, which established 
300  mg daily as the maximum tolerated dose.42 Dose­
limiting toxic effects reported in the first cycle were grade 
3 fatigue (1 patient given 30 mg/day), grade 3 pneumo­
nitis (1 patient given 60  mg/day), and grade 4 throm­
bocytopenia (2 patients given 400   mg/day). Included 
in the trial were 22 patients with BRCA1/2-mutated 
ovarian or primary peritoneal cancer, of whom 20 were 
radiologically assessable. Eight (40%) of these 20 patients 
achieved a confirmed RECIST and Gynecologic Cancer 
Intergroup CA 125 partial response at doses ranging from 
Table 1. PARP Inhibitors in Clinical Development
PARP Inhibitor Route
Phase of 
Development
Olaparib AZD­2281 PO Phase 1­3
Rucaparib CO­338 PO Phase 1­3
Veliparib ABT­888 PO Phase 1­3
Niraparib MK­4827 PO Phase 1­3
Talazoparib BMN­673 PO Phase 1­2
PARP, poly(adenosine diphosphate­ribose) polymerase inhibitor;  
PO, by mouth.
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80 to 400 mg per day with a median response duration 
of 387 days.42 Responses also were observed in platinum­
sensitive and platinum­resistant sporadic ovarian cancers. 
Treatment­related adverse events were mostly grade 1 or 
2, and included anemia (48%), fatigue (42%), throm­
bocytopenia (35%), neutropenia (24%), and anorexia 
(26%). In a phase 3 trial of niraparib vs placebo as main­
tenance therapy called NOVA (A Maintenance Study 
With Niraparib Versus Placebo in Patients With Platinum 
Sensitive Ovarian Cancer; NCT01847274), patients with 
platinum­sensitive high­grade serous ovarian cancer were 
randomly assigned in a 2:1 ratio to receive either niraparib 
or placebo. The agent’s manufacturer announced in June 
that niraparib significantly improved PFS in patients with 
germline BRCA mutations and in those without germline 
BRCA mutations who had homologous recombination–
deficient tumors43; full results will be presented later this 
year. Two additional trials of niraparib in ovarian cancer 
are underway: a single­arm phase 2 study in patients with 
high­grade serous ovarian cancer who have received 3 or 
more prior lines of chemotherapy called QUADRA (A 
Study of Niraparib in Patients With Ovarian Cancer Who 
Have Received Three or Four Previous Chemotherapy 
Regimens; NCT02354586; Table 2) and a phase 1/2 
combination study with bevacizumab called AVANOVA 
(Niraparib and/or Niraparib­Bevacizumab Combination 
Against Bevacizumab Alone in HRD Platinum Sensitive 
Ovarian Cancer; NCT02354131; Table 3). 
Veliparib 
Veliparib is an oral bioavailable PARP­1/2 inhibitor that 
has been predominately studied in combination with 
Table 2. Ongoing PARP Inhibitor Single­Agent Studies
NCT Identifier 
Number Phase Trial type
Platinum 
Status
Previous Lines of 
Treatment Inclusion Criteria
PARP 
Inhibitor Comparator
NCT01482715 2 Maintenance PS ≥3 chemotherapy
BRCA1/2 
(germline or 
somatic)
Rucaparib NA
NCT01968213 
(ARIEL3) 3 Maintenance PS ≥2 platinum
HGSOFPC or 
endometrioid 
cancer
Rucaparib Placebo
NCT02354586
(QUADRA) 2 Single­arm PS ≥3 chemotherapy
HGSOFPC or 
endometrioid 
cancer
Niraparib NA
ARIEL3, A Study of Rucaparib as Switch Maintenance Following Platinum­Based Chemotherapy in Patients With Platinum­Sensitive, High­Grade 
Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer; HGSOFPC, high­grade serous ovarian, fallopian tube, or 
primary peritoneal cancer; NA, not available; PARP; poly(adenosine diphosphate­ribose) polymerase; PS, platinum­sensitive; QUADRA, A Study of 
Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens.
Table 3. Ongoing Early­Phase PARP Inhibitor Combination Studies
NCT Identifier 
Number Phase
PARP 
Inhibitor Combination Inclusion Criteria BRCA Status
NCT02354131 
(AVANOVA) 1/2 Niraparib Bevacizumab (VEGF)
HGSOFPC,  
PS to ≥1 platinum Mutant and WT
NCT02358200 1 Talazoparib Carboplatin and paclitaxel BRCA1/2­mutant solid tumor or TN breast Mutant
NCT02627430 1 Talazoparib AT13387 (HSP90 inhibitor) Advanced solid tumour, EOFPC, or TN breast Mutant and WT
NCT01145430 1 Veliparib PLD EOFPC or TN breast Mutant and WT
NCT00989651 1 Veliparib Carboplatin, paclitaxel,  and bevacizumab HGSOFPC, treatment­naive Mutant and WT
AVANOVA, Niraparib and/or Niraparib­Bevacizumab Combination Against Bevacizumab Alone in HRD Platinum Sensitive Ovarian Cancer; 
EOFPC, epithelial ovarian, fallopian tube, or primary peritoneal carcinoma; HGSOFPC, high­grade serous ovarian, fallopian tube, or primary 
peritoneal cancer; HSP90, heat shock protein 90; PARP; poly(adenosine diphosphate­ribose) polymerase; PLD, pegylated liposomal doxorubicin; 
PS, platinum­sensitive; TN, triple­negative; VEGF, vascular endothelial growth factor; WT, wild­type.
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cytotoxic chemotherapy. Phase 1 studies have been per­
formed using veliparib in combination with top otecan, 
doxorubicin, and cyclophosphamide (both oral and 
intravenous), with significant myelosuppression observed 
when combined with DNA­damaging agents.44­46 The 
combination of veliparib and topotecan led to significant 
myelosuppression, necessitating dose reductions. The 
maximum tolerated dose was established as topotecan 
0.6 mg/m2 per day and veliparib 10 mg twice a day on 
days 1 to 5 of each 21­day cycle.44 No responses to treat­
ment were reported.44 For recurrent, platinum­resistant 
high­grade serous ovarian cancer, the combination of 
veliparib and temozolomide is currently being tested vs 
pegylated liposomal doxorubicin (NCT01113957). The 
combination of veliparib and metronomic cyclophospha­
mide (50 mg once daily) was well tolerated, with grade 
2 myelosuppression the most common dose­limiting 
toxicity in the phase 1 trial. Although responses were 
observed in patients with known BRCA1/2 mutations (6 
out of 13 patients) in the phase 1 trial,45 the combina­
tion of veliparib and cyclophosphamide failed to improve 
the response rate or PFS vs cyclophosphamide alone in 
a randomized phase 2 trial in patients with BRCA1/2­
mutant high­grade ovarian cancer.47 The platinum sensi­
tivity status of tumors in this trial was unknown. Other 
ongoing veliparib and chemotherapy combination trials 
include the Gynecologic Oncology Group phase 1 study 
with carboplatin, paclitaxel, and bevacizumab (Avastin, 
Genentech; NCT00989651). 
The role of veliparib as a single agent was recently 
explored in a single­arm phase 2 study in 50 ovarian can­
cer patients with germline BRCA1/2 mutations who had 
received 3 or fewer chemotherapy regimens.48 In 60% of 
patients, the disease was considered platinum­resistant. 
The overall response rate was 26% (90% CI, 16%­38%), 
the response rate for platinum­resistant disease was 20%, 
and the response rate for platinum­sensitive disease 
was 35%.48 Grade 3 adverse events included fatigue (3 
patients), nausea (2 patients), and neutropenia (1 patient), 
with the most common grade 2 events including nausea 
(46%), vomiting (18%), and anemia (14%). The role of 
veliparib vs placebo in combination with carboplatin and 
paclitaxel and then as maintenance therapy in newly diag­
nosed high­grade serous ovarian cancer (stages III and IV) 
is currently undergoing evaluation in a randomized phase 
3 trial (NCT02470585, Table 4). 
Talazoparib
Talazoparib is a potent PARP­1/2 inhibitor that selec­
tively targets BRCA1/2-mutant tumor cells in preclinical 
models. Its potency is 20­ to 200­fold greater than that of 
other PARP­1/2 inhibitors, such as olaparib, rucaparib, 
and veliparib.49 In the phase 1 dose­escalation study, 39 
patients were enrolled in 9 cohorts and received doses 
from 25 to 1100 µg per day, resulting in the establishment 
of 1000 µg per day as the maximum tolerated dose. A total 
of 17 patients with BRCA1/2­mutant high­grade ovarian 
cancer were included and treated with doses of at least 100 
µg per day. Within this group, RECIST and/or CA 125 
responses were observed in 11 patients.50 Dose­limiting 
thrombocytopenia occurred in 1 of 6 patients receiving 
900 µg per day and 2 of 5 patients receiving 1100 µg 
per day. Potentially related adverse events included fatigue 
(10 patients), nausea (10 patients), anemia (6 patients, 
including 2 with grade 3/4), neutropenia (7 patients, 
including 3 with grade 3/4), and thrombocytopenia (4 
patients, including 3 with grade 3/4). A single­arm phase 
2 study is currently underway evaluating talazoparib activ­
ity in platinum­sensitive BRCA1/2-mutant solid tumors 
(NCT01989546), with phase 3 trials ongoing in meta­
static breast cancer but not in ovarian cancer. Whether 
this more­potent PARP inhibitor has activity following 
progression on another PARP inhibitor is currently being 
evaluated (NCT02326844). This phase 2, single­arm 
study is examining the role of talazoparib in patients with 
BRCA1/2-associated ovarian cancer who have received 
prior PARP inhibitor therapy. Eligible patients must have 
progressed on prior PARP inhibitor monotherapy after 
attaining a response (complete response, partial response, 
or stable disease for ≥4 months). This study addresses an 
important issue as to whether rechallenge with an alterna­
tive PARP inhibitor can induce further clinical response. 
Table 4. Ongoing Randomized Phase 3 PARP Inhibitor Combination Studies
NCT Identifier 
Number Phase
PARP 
Inhibitor Combination
Platinum 
Status Inclusion Criteria
NCT02470585 3 Veliparib
Veliparib or placebo in combination 
with carboplatin and paclitaxel and as 
maintenance therapy
First­line 
treatment HGSOFPC, stage III/IV
NCT01113957 2 Veliparib Veliparib and temozolomide or PLD Platinum­resistant HGSOFPC
HGSOFPC, high­grade serous ovarian, fallopian tube, or primary peritoneal cancer; PARP; poly(adenosine diphosphate­ribose) polymerase; PLD, 
pegylated liposomal doxorubicin.
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Resistance to PARP Inhibitors
Despite promising response rates to PARP inhibition in 
BRCA-mutant and other homologous recombination–
deficient tumors, de novo and acquired resistance are 
significant clinical problems. One surprising mechanism 
of resistance observed in vitro is the development of sec­
ondary mutations in BRCA1 or BRCA2 that restore the 
open reading frame of the gene, enabling translation of 
the functional BRCA protein and the ability to repair the 
DNA damage caused by PARP inhibitors (and platinum 
salts).51,52 Similar BRCA1/2 reversion mutations have 
been observed in platinum­resistant and PARP inhibi­
tor–refractory disease,53,54 with up to 46% of patients 
with platinum­resistant disease harboring tumor­specific 
secondary mutations that restored the open reading frame 
of either BRCA1 or BRCA2.53 
A second observed resistance mechanism occurs via 
reduced activity of nonhomologous end joining due to 
loss of 53BP1. Loss of 53BP1 in cell­line and animal 
models restores homologous recombination activity in 
BRCA1-mutant cells, leading to olaparib resistance.55 
Interestingly, sensitivity to cisplatin is maintained, pos­
sibly owing to the more complex nature of the DNA 
cross­link lesions induced by cisplatin.55 The importance 
of 53BP1 in clinical resistance to PARP inhibitors is not 
clear, but it may be one mechanism by which ongoing 
platinum responses are observed after PARP inhibitor 
therapy.9,56 Although the above resistance mechanism 
involves changes in the DNA damage response mediat­
ing resistance, pharmacologic effects that alter the cel­
lular response to PARP inhibitors also may be relevant. 
Increased expression of adenosine triphosphate (ATP)­
binding cassette transporters, which are transmembrane 
proteins that shuttle substrates across extracellular 
and intracellular membranes, alters PARP inhibitor 
response.57,58 The contribution of ATP­binding cassette 
transporter overexpression to PARP inhibitor resistance 
in clinical samples has yet to be established. 
To date, clinical studies evaluating PARP inhibitor 
resistance mechanisms have been performed in only small 
numbers of patients. Additional studies are required to 
conclusively define the frequency of various resistance 
mechanisms for both acquired and de novo PARP 
inhibitor resistance. Clearly under the selective pressure 
of PARP inhibition (and indeed platinum treatment), the 
high­grade ovarian cancer genome is able to adapt in a 
number of ways, and overcoming resistance will require 
a variety of approaches. Further clarification of resistance 
mechanisms will aid in the discovery of novel approaches 
to overcome PARP inhibitor resistance, and may help 
determine the optimal sequence of these agents in the 
management of ovarian cancer. 
Conclusions and Future Directions
Although it is clear that a benefit exists for PARP inhibi­
tors in EOC characterized by BRCA1/2 mutations, there 
is also a role in tumors displaying the BRCAness pheno­
type, which harbor homologous recombination defects 
via alternative mechanisms. Furthermore, there may be 
an additional role for PARP inhibition in EOCs that are 
traditionally thought to be homologous recombination–
proficient, such as nonserous histology, or those charac­
terized by mutations in nonhomologous recombination 
genes, such as PTEN, that may modulate homologous 
recombination pathways. It remains unclear what deter­
mines the best predicator of response to PARP inhibition, 
although a number of clinical trials are ongoing that 
are beginning to address this. Furthermore, it is not yet 
established how to optimize the use of PARP inhibitors 
(eg, as single agents, in combination with chemotherapy/
targeted therapy, or as maintenance therapy) or whether 
clinical differences exist among PARP inhibitors. As yet, 
there are no ongoing direct comparative trials to evaluate 
for differences in efficacy and/or toxicity between PARP 
inhibitors, although these may become necessary if the 
newer PARP inhibitors prove efficacious. 
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